Alunbrig (brigatinib) vs Tabrecta (capmatinib)

Alunbrig (brigatinib) and Tabrecta (capmatinib) are both targeted therapies used to treat non-small cell lung cancer (NSCLC), but they are designed to target different genetic mutations. Alunbrig is specifically indicated for patients with NSCLC that is anaplastic lymphoma kinase-positive (ALK+), following the failure of crizotinib, another ALK inhibitor. In contrast, Tabrecta is approved for the treatment of adult patients with metastatic NSCLC that have mutations leading to mesenchymal-epithelial transition (MET) exon 14 skipping, and it is not dependent on prior treatment with other medications. When deciding between these two medications, it is essential to have molecular testing to determine the presence of either the ALK+ or MET exon 14 skipping mutation in the tumor, as this will guide the choice of treatment.

Difference between Alunbrig and Tabrecta

Metric	Alunbrig (brigatinib)	Tabrecta (capmatinib)
Generic name	Brigatinib	Capmatinib
Indications	Non-small cell lung cancer (NSCLC) with ALK mutations	Non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations
Mechanism of action	ALK inhibitor	MET inhibitor
Brand names	Alunbrig	Tabrecta
Administrative route	Oral	Oral
Side effects	Fatigue, cough, headache, and increased blood pressure	Nausea, vomiting, fatigue, and edema
Contraindications	Hypersensitivity to brigatinib or any component of the formulation	Hypersensitivity to capmatinib or any component of the formulation
Drug class	Tyrosine kinase inhibitor	Tyrosine kinase inhibitor
Manufacturer	Takeda Pharmaceuticals U.S.A., Inc.	Novartis Pharmaceuticals Corporation

Efficacy

Alunbrig (Brigatinib) Efficacy in Lung Cancer

Alunbrig (brigatinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with a specific genetic alteration, an anaplastic lymphoma kinase (ALK) mutation. The efficacy of Alunbrig in treating ALK-positive NSCLC was demonstrated in clinical trials, where patients treated with brigatinib showed a significant improvement in progression-free survival compared to those who received crizotinib, another ALK inhibitor. This improvement indicates that Alunbrig can effectively delay the progression of lung cancer in patients with the ALK mutation.

In addition to progression-free survival, the response rate to Alunbrig in patients with ALK-positive NSCLC has been found to be high, with many patients experiencing a reduction in tumor size. This response is particularly notable in patients who have progressed on or are intolerant to previous ALK inhibitor therapy. Furthermore, Alunbrig has shown activity in the central nervous system, which is important given the propensity for ALK-positive NSCLC to metastasize to the brain.

Tabrecta (Capmatinib) Efficacy in Lung Cancer

Tabrecta (capmatinib) is another targeted therapy, specifically for the treatment of metastatic NSCLC with mutations that lead to MET exon 14 skipping. The efficacy of Tabrecta was evaluated in a multicenter, non-randomized, open-label, multi-cohort study. The results demonstrated that patients with MET exon 14 skipping mutations had a substantial overall response rate, indicating that Tabrecta is effective in shrinking tumors in this subset of NSCLC patients.

Moreover, the duration of response for patients treated with Tabrecta was noteworthy, with many patients maintaining their response for a significant period. This durability of response is a critical aspect of treatment effectiveness for patients with advanced lung cancer. Tabrecta has also shown promise in patients who have previously received systemic therapy, suggesting its potential use as a second-line treatment for MET exon 14-altered NSCLC.

Regulatory Agency Approvals

Alunbrig

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Tabrecta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Alunbrig or Tabrecta today

If Alunbrig or Tabrecta are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Alunbrig

Buy Tabrecta

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: